Wanbury launches nitrofurantoin sustained-release in India
This article was originally published in Scrip
Executive Summary
Wanbury of India has launched nitrofurantoin 100mg sustained-release (marketed as Nitrofur SR) for the treatment of urinary tract infections (UTI) on the domestic market. The product, which is based on hydrophilic polymer matrix technology, offers a once-daily dosage. Currently, competing products fall in the instant-release category and need to be taken four times a day, often with side-effects such as gastrointestinal irritation and burning sensation, leading to poor patient compliance. The market for UTIs in India is estimated at about Rs12 billion ($247.3 million) and is growing at 14% per year. Wanbury is targeting sales of Rs100 million from Nitrofur SR in the first year. Wanbury, which was originally formed by the merger of Wander and Pearl Organics in India, is a manufacturer of metformin hydrochloride. Wander was originally a subsidiary of Sandoz, but the Indian founders took control of the company in 1995.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.